Page 149 - JSOM Winter 2018

45. McAlindon TE, LaValley MP, Gulin JP, et al. Glucosamine 67. Pujalte JM, Llavore EP, Ylescupidez FR. Double-blind clinical
and chrondrotin for treatment of osteoarthritis: a systematic qual- evaluation of oral glucosamine sulfate in the basic treatment of
ity assessment and meta-analysis. JAMA. 2000;283(11):1469– osteoarthritis. Curr Med Res Opin. 1980;7(2):110–114.
1475. 68. Drovanti A, Bignamini AA, Rovati AL. Theraputic activity of
46. Poolsup N, Suthisisang C, Channark P, et al. Glucosamine long- oral glucosamine sulfate in osteoarthritis: a placebo-controlled
term treatment and the progression of knee osteoarthritis: system- double-blind investigation. Clin Ther. 1980;3(4):260–272.
atic review of randomized controlled trials. Ann Pharmacother. 69. Noack W, Fischer M, Forster KK, et al. Glucosamine sulfate in os-
2005;39:1080–1087. teoarthritis of the knee. Osteoarthritis Cartilage. 1994;2:51–59.
47. Bjordal JM, Klovning A, Ljunggren AE, et al. Short-term efficacy 70. Usha PR, Naidu MUR. Randomized, double-blind, parallel,
of pharmacotherapeutic interventions in osteoarthritis knee pain: placebo-controlled study of oral glucosamine, methylsulfonyl-
a meta-analysis of randomized placebo controlled trials. Eur J methane and their combination in osteoarthrtis. Clin Drug Inves-
Pain. 2007;11:125–138. tig. 2004;24(6):353–363.
48. Richy F, Bruyere O, Ethgen O, et al. Structural and symptom- 71. Rindone JP, Hiller D, Collacott E, et al. Randomized, controlled
atic efficacy of glucosamine and chondroitin in knee osteoarth- trial of glucosamine for treating osteoarthritis of the knee. West J
ritis. A comprehensive meta-analysis. Arch Int Med. 2003;163: Med. 2000;172(2):91–95.
1514–1522. 72. Chopra A, Saluja M, Tillu G, et al. A randomized controlled
49. Knapik JJ, Austin KG, Farina EK, et al. Dietary supplement use in exploratory evaluation of standardized Ayurvedic formulations
a large, representative sample of the United States Armed Forces. in symptomatic osteoarthritis knees: a government of India
J Acad Nutr Diet. In press. NMITLI project. Evid Based Complement Alternat Med. 2011;
50. Knapik JJ, Steelman R, Hoedebecke S, et al. A systematic review 2011:724291.
and meta-analysis on the prevalence of dietary supplement use by 73. Hughes R, Carr A. A randomized, double-blind, placebo-con-
military personnel. BMC Complement Altern Med. 2014;14:143. trolled trial of glucosamine sulfate as an alalgesic in osteoarthritis
51. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items of the knee. Rheumatology. 2002;41:279–284.
for systematic reviews and meta-analyses: the PRISMA statement. 74. Giordano N, Fioravanti A, Papakostas P, et al. The efficacy and
PLoS Med. 2009;6(7):e1000097. tolerability of glucosamine sulfate in the treatment of knee osteo-
52. Downs SH, Black N. The feasibility of creating a checklist for the arthritis: a randomized, double-blind, placebo-controlled trail.
assessment of the methodological quality both of randomized and Curr Ther Res. 2009;70(3):185–196.
non-randomized studies of healthcare interventions. J Epidemiol 75. Cahlin BJ, Dahlstrom L. No effect of glucosamine sulfate on
Community Health. 1998;52:377–384. osteoarthritis in the temporomandibulat joints—a randomized,
53. Cohen J. A power primer. Psychol Bull. 1992;112(1):155–159. controlled short-term study. Oral Surg Oral Med Oral Parhol
54. Follmann D, Elliott P, Suh I, et al. Variance imputation for over- Oral Radiol Endod. 2011;112:760–766.
views of clinical trials with continuous response. J Clin Epide- 76. McAlindon T, Formica M, Lehmer MLM, et al. Effectiveness of
miol. 1992;45(7):769–773. glucosamne for symptoms of knee osteoarthritis: results from an
55. Higgins JPT, Green S. Cochrane Handbook for Systematic Re- internet-based randomized double-blind controlled trail. Am J
views of Interventions. http://handbook-5-1.cochrane.org/front Med. 2004;117:643–649.
_page.htm. Accessed 14 March 2018. 77. Herrero-Beaumont G, Ivorra JAR, DelCarmenTabado M, et al.
56. Lipsey MW, Wilson D: Practical Meta-Analysis. Thousand Oaks Glucosamine sulfate in the treatment of knee osteoarthritis symp-
CA: Sage Publications, Inc; 2001. toms. Arthritis Rheumatol. 2007;56(2):555–567.
57. Huedo-Medina T, Sanchez-Meca J, Marin-Martinez F, et al. As- 78. Higgins JPT. Commentary: hetergeneity in meta-analysis should
sessing heterogeneity in meta-analysis: Q-statistic or I index? be expected and appropiately quantified. Int J Epidemiol. 2008;
2
Psychol Methods. 2006;11(2):193–206. 37:1158–1160.
58. Higgins JPT, Thompson SG, Deeks JJ, et al. Measuring inconsis- 79. DeWan M, Volpi G. Method of preaparing mixed glucosamine
tency in meta-analysis. Br Med J. 2003;327:557–560. salts. https://patents.justia.com/patent/5847107. Accessed 10 May
59. Begg CB, Mazumdar M. Operating characteristics of a rank or- 2018.
der correlation test for publication bias. Biometrics. 1994;50(4): 80. Russell AS, Aghazadeh-Habashi A, Jamali F. Active ingredient
1088–1101. consistency of commerically available glucosamine sulfate prod-
60. Rozendaal RM, Koes BW, VanOsch GJVM, et al. Effect of glu- ucts. J Rheumatol. 2002;29:2407–2409.
cosamine sulfate on hip osteoarthritis. A randomized trial. Ann 81. Aghazadeh-Habashi A, Duke J, Jamali F. The impact of impli-
Intern Med. 2008;148:268–277. mentation of the Canadian Regulatory Requirements on the
61. Rozendaal RM, Ultterlinden EJ, VanOsch GJVM, et al. Effect of quality of natural health products: the glucosamine case. J Pharm
glucosamine sulfate on joint space narrowing, pain and function in Pharm Sci. 2014;17(1):20–24.
patients with hip osteoarthritis; subgroup analysis of a ramdom- 82. Santos GRC, Piquet AA, Glauser BF, et al. Systematic analysis
ized controlled trail. Osteoarthritis Cartilage. 2008;17:427–432. of pharmaceutical preparations of chondroitin sulfate combined
62. Zenk JL, Helmer TR, Kuskoeski MA. The effects of milk pro- with glucosamine. Pharmaceuticals. 2017;10:38.
tein concentrate on the symptoms of osteoarthritis in adults: an 83. Setnikar I, Rovati LC. Absorption, distribution, metabolism
exploratory, randomized, double-blind, placebo-controlled trial. and excretion of glucosamine sulfate. A review. Arzneimittelfor-
Curr Ther Res. 2002;63(7):430–442. schung. 2001;51(9):699–725.
63. Frestedt JL, Walsh M, Kuskowski MA, et al. A natural mineral 84. Chiusaroli R, Piepoli T, Zanelli T, et al. Experimental pharmacol-
supplement provides relief from knee osteoarthritis symptoms: a ogy of glucosamine sulfate Int J Rheumatol. 2011;2011:939265.
randomized controlled pilot trial. Nutr J. 2008;7:9. 85. Saengnipanthkul S, Waikakul S, Rojanasthien S, et al. Differen-
64. Reginster JY, Deroisy R, Rovati LC, et al. Long-term effects of tation of patented crystalline glucosamine sulfate from other glu-
gluocosamine sulfate on osteoarthritis progression: a randomized, cosamine preparations will optimize osteoarthritis treatment. Int
placebo-controlled clinical trial. Lancet. 2001;357:251–256. J Rheumatic Dis. 23 March 2017; e-pub ahead of print.
65. Pavelka K, Gatterova J, Olejarova M, et al. Glucosamine sulfate 86. Largo R, Alvarez-Soria MA, Diez-Ortego I, et al. Glucosamine
use and delay of progression of knee osteoarthritis. A 3-year, ran- inhibits IL-1B-inducted NFkB activation in human osteoarthritic
domized, placebo-controlled, double-blind study Arch Int Med. chondrocytes. Osteoarthritis Cartilage. 2003;11:290–298.
2002;162:2113–2123. 87. Persiani S, Rotini R, Trisolino G, et al. Synovial and plasma glu-
66. Fransen M, Agaliotis M, Nairn L, et al. Glucosamine and con- cosamine concentration in osteoarthritic patients following oral
droitin for knee arthritis: a double-blind randomized placebo- crystalline glucosamine sulfate at therapeutic dose. Osteoarthritis
controlled clinical trial evaluating single and combination regi- Cartilage. 2007;15:764–772.
mens. Ann Rheum Dis. 2015;74:851–858.

Osteoarthritis and Glucosamine | 147